FIGURE 1.

Kaplan–Meier estimates of progression‐free survival or disease‐free survival* for osimertinib and its metabolite, AZ5104, respectively, in patients receiving osimertinib in ≥second‐line (A and B), first‐line (C and D) or adjuvant settings (E and F). Curves were stratified by quartiles of osimertinib or AZ5104 AUC_ss. The solid black line shows progression‐free survival or disease‐free survival for the comparator treatment (platinum‐pemetrexed in AURA3, no comparator in AURA or AURA2, comparator epidermal growth factor receptor‐tyrosine kinase inhibitors in FLAURA and placebo in ADAURA). The shaded area represents the 95% CI range. *In ADAURA, the median disease‐free survival was not reached at the 17 January 2020 data cut‐off; therefore, median disease‐free survival could not be calculated for the osimertinib and AZ5104 AUC_ss quartiles. AUC_ss, area under the curve at steady state; CI, confidence interval; HR, hazard ratio; PFS, progression‐free survival.